Value
6.4/10data confidence 100%| Component | Sub-score |
|---|---|
| P/E | 4.5 |
| P/S | 4.9 |
| EV/EBITDA | 0.9 |
| Fwd P/E | 7.6 |
| PEG | 8.6 |
| Analyst target | 9.0 |
- ▸Forward P/E: 16.1x
- ▸PEG: 0.73
VEEV · Why this verdict
Why Veeva Systems (VEEV) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.9/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Veeva Systems is a best-in-class life sciences software business with 28% net margins, 134% free cash flow conversion, and a four-quarter earnings beat streak, but a confirmed price downtrend with the 50-day moving average crossing below the 200-day moving average blocks near-term entry despite attractive analyst upside of 51%.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Veeva earns 28% net margins, converts 134% of net income to free cash flow, and passes the Rule of 40 with a score of 54, collectively placing it in the top tier of healthcare software companies for durable cash-generating quality. Quality breakdown | Net margins remain above 24% and the Rule of 40 score stays above 45 over the next four quarters, confirming the margin structure is not eroding. | →Stable |
| CounterVeeva's concentration in North American life sciences clients means that any slowdown in pharma R&D spending or consolidation among large biotech customers could reduce seat expansion and compress margins faster than the Rule of 40 score currently implies. | ||
Veeva has exceeded quarterly earnings per share estimates in all four of the most recent quarters with an average surprise of 5.2%, demonstrating a track record of reliable execution against analyst expectations even as the stock has underperformed. Earnings | Veeva beats earnings estimates in at least 3 of the next 4 quarters, continuing the streak and providing a fundamental floor that limits downside risk. | →Stable |
| CounterFive percent average beats are modest and suggest management has already tightened guidance to a level close to actual performance; the beat streak may not be sustainable if analyst models become more precise or if revenue growth decelerates. | ||
Veeva's 50-day moving average has crossed below the 200-day moving average, which is confirmed by a momentum score of 1.7 and falling on-balance volume, indicating that the weight of institutional selling has been dominant and the price trend remains negative. Warnings | The 50-day moving average rises back above the 200-day moving average within 6 months, and on-balance volume trends turn positive, signaling technical recovery and a more favorable entry window. | →Stable |
| CounterMoving average crossovers in software stocks with strong fundamentals sometimes produce false signals; Veeva's RSI of 53 in a mid-range position and favorable reward-to-risk ratio of 5.2x suggest the downtrend may be exhausting itself. | ||
Analysts see 51% upside to a consensus target of approximately $221, reflecting confidence in Veeva's dominant position in life sciences cloud software, but revenue concentration in North America limits the total addressable market expansion story. Bear case | Veeva's non-North American revenue share grows to at least 25% within 12 months, reducing geographic concentration while the stock price rises above $190. | →Stable |
| CounterEuropean and Asia-Pacific pharma companies have slower regulatory software adoption cycles and different data sovereignty requirements that have historically made international expansion more costly and slower for Veeva than its North American core. | ||
Veeva earns 28% net margins, converts 134% of net income to free cash flow, and passes the Rule of 40 with a score of 54, collectively placing it in the top tier of healthcare software companies for durable cash-generating quality.
→StableQuality breakdown
- Expectation
- Net margins remain above 24% and the Rule of 40 score stays above 45 over the next four quarters, confirming the margin structure is not eroding.
CounterVeeva's concentration in North American life sciences clients means that any slowdown in pharma R&D spending or consolidation among large biotech customers could reduce seat expansion and compress margins faster than the Rule of 40 score currently implies.
Veeva has exceeded quarterly earnings per share estimates in all four of the most recent quarters with an average surprise of 5.2%, demonstrating a track record of reliable execution against analyst expectations even as the stock has underperformed.
→StableEarnings
- Expectation
- Veeva beats earnings estimates in at least 3 of the next 4 quarters, continuing the streak and providing a fundamental floor that limits downside risk.
CounterFive percent average beats are modest and suggest management has already tightened guidance to a level close to actual performance; the beat streak may not be sustainable if analyst models become more precise or if revenue growth decelerates.
Veeva's 50-day moving average has crossed below the 200-day moving average, which is confirmed by a momentum score of 1.7 and falling on-balance volume, indicating that the weight of institutional selling has been dominant and the price trend remains negative.
→StableWarnings
- Expectation
- The 50-day moving average rises back above the 200-day moving average within 6 months, and on-balance volume trends turn positive, signaling technical recovery and a more favorable entry window.
CounterMoving average crossovers in software stocks with strong fundamentals sometimes produce false signals; Veeva's RSI of 53 in a mid-range position and favorable reward-to-risk ratio of 5.2x suggest the downtrend may be exhausting itself.
Analysts see 51% upside to a consensus target of approximately $221, reflecting confidence in Veeva's dominant position in life sciences cloud software, but revenue concentration in North America limits the total addressable market expansion story.
→StableBear case
- Expectation
- Veeva's non-North American revenue share grows to at least 25% within 12 months, reducing geographic concentration while the stock price rises above $190.
CounterEuropean and Asia-Pacific pharma companies have slower regulatory software adoption cycles and different data sovereignty requirements that have historically made international expansion more costly and slower for Veeva than its North American core.
Per-dimension breakdown
Quality
8.2/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 4.6 |
| ROA | 4.9 |
| Gross margin | 10.0 |
| Op margin | 10.0 |
| Net margin | 10.0 |
| Current ratio | 8.3 |
| FCF quality | 9.5 |
| Moat | 6.9 |
| Rule of 40 | 8.8 |
| Piotroski F | 8.9 |
- ▸Strong margins: 28%
- ▸Excellent cash conversion: 134% FCF/NI
- ▸Rule of 40: 54 (pass)
- ▸Strong Piotroski F-Score: 8/9
Growth
5.8/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 6.6 |
| EPS growth | 4.9 |
Momentum
2.8/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.0 |
| MACD | 0.0 |
| OBV | 10.0 |
| MA position | 1.0 |
| Volume | 0.0 |
- ▸Capitulation risk (RSI 29, below 200MA)
- ▸Volume accumulation (rising OBV)
- ▸Below 200-MA, MA slope -7.5%/30d — confirmed downtrend
Sentiment
7.8/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 6.5 |
| Analyst rating | 7.5 |
| Price target | 9.6 |
- ▸Analyst upside: 53%
Insider
5.0/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 5.1 |
- ▸Negligible insider selling — $231,855 (0.001% of mkt cap)
Peer rank
5.3/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 3.7 |
| quality rank | 8.2 |
| growth rank | 4.2 |
- ▸Best-in-class margins
Technical
4.9/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 6.6 |
| support resistance | 7.7 |
| 52w position | 0.3 |
Risk (lower is worse)
5.2/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 7.1 |
| days to cover | 8.8 |
| volatility | 2.2 |
| put call | 3.6 |
| implied vol | 5.3 |
| max pain risk | 3.0 |
| beta | 7.3 |
| debt equity | 4.2 |
- ▸Above max pain $135
- ▸Concentration risks: 1 HIGH, 1 MED (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
6.0/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 5.1 |
| news activity | 5.0 |
- ▸Perfect beat streak: 4Q
How the verdict was assembled
Engine trigger
Multiple concerning factors. Consider reducing position.
Engine technical detail
verdict_path:
L4:PATH_F_SELLPassed (5)
- ASYMMETRY:4.6>=1.5
- INSIDER:OK
- EARNINGS_PROXIMITY:69d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (2)
- MOMENTUM:2.8<4.5
- DEATH_CROSS:HARD_BLOCK
Warning (1)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
4.63
Upside
+38.1%
Downside
8.2%
Sizing output
AVOID
SetupFALLING_KNIFE — Death cross, below all MAs, RSI 29, MACD bearish
EdgeTEMP_HEADWIND — High quality (8.2) with weak momentum (2.8)
SuitabilityMODERATE — Balanced profile
Investment implication
The F-path SELL output reflects an overall score of 5.4 below the 5.6 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. The strongest dimension ( Quality at 8.2) was not enough to lift the adjusted overall above the threshold. Co-occurring failed gates ( MOMENTUM:2.8<4.5, DEATH_CROSS:HARD_BLOCK) reinforce the read. Current asymmetry R:R is 4.63 — supplementary context, not the trigger for this path.
The strongest dimensions are Quality at 8.2, Sentiment at 7.8, and Value at 6.4; the weakest are Momentum at 2.8, Technical at 4.9, and Insider at 5.0. The V9 engine flagged 2 failed gates with 1 warning, producing an asymmetric reward-to-risk of 4.63 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Veeva earns 28% net margins, converts 134% of net income to free cash flow, and passes the Rule of 40 with a score of 54, collectively placing it in the top tier of healthcare software companies for durable cash-generating quality.
Trip ifNet margin falls below 20% for 2 consecutive quarters, indicating the high-margin structure is deteriorating.
- P2Veeva has exceeded quarterly earnings per share estimates in all four of the most recent quarters with an average surprise of 5.2%, demonstrating a track record of reliable execution against analyst expectations even as the stock has underperformed.
Trip ifEPS surprise falls below 0% in at least 2 of the next 4 quarters, ending the consistent execution record.
- P3Veeva's 50-day moving average has crossed below the 200-day moving average, which is confirmed by a momentum score of 1.7 and falling on-balance volume, indicating that the weight of institutional selling has been dominant and the price trend remains negative.
Trip ifStock price drops below $140, more than 13% below the current $162.17, with the death cross persisting for more than 4 months.
- P4Analysts see 51% upside to a consensus target of approximately $221, reflecting confidence in Veeva's dominant position in life sciences cloud software, but revenue concentration in North America limits the total addressable market expansion story.
Trip ifInternational revenue remains below 20% of total for 3 consecutive years while North American growth decelerates below 8% annually.